Program
macupatide
Also written as “LY3532226” and “Macupatide”.
Its studies are mostly in Obesity · Diabetes Mellitus, Type 2 · Diabetes Mellitus, Type 1, led by Eli Lilly.
Furthest: phase 2, since Nov 6, 20238 company-led studies, 4 open or runningNext primary completion: Mar 2027 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Eli Lilly | 84 open or running | phase 2since Nov 6, 2023 | Jun 9, 2021 | Mar 2027phase 2 · NCT07215559 |
- Named in Eli Lilly’s own pipeline as
Macupatide + Eloralintide
, phase 2, as of Oct 29, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jun 9, 2021First study: phase 1 study in HealthyFirst studyNCT04923269 · 41 enrolled · Singapore
- May 26, 2022Phase 1 study in Diabetes Mellitus, Type 2NCT05407961 · 90 enrolled · Germany
- May 25, 2023Phase 1 study in Diabetes Mellitus, Type 1NCT05887999 · 30 enrolled · United States
- Nov 6, 2023Phase 2 study in ObesityNCT06143956 · 1,481 planned · United States, Argentina
- Aug 14, 2024Phase 1 study in ObesityNCT06557356 · 132 enrolled · United States, Singapore
- Oct 9, 2025Phase 2 study in ObesityNCT07215559 · 200 enrolled · United States, Argentina, Australia and more
- May 11, 2026Phase 2 study in OverweightNCT07589608 · 400 planned · United States
- Aug 11, 2026Phase 1 study in ObesityNCT07765511 · 60 planned · Japan
Ahead
- Mar 2027Primary completion: phase 2 study in ObesityNCT07215559
- Jun 2027Primary completion: phase 1 study in ObesityNCT07765511
- Sep 2027Primary completion: phase 2 study in OverweightNCT07589608
- Sep 2027Primary completion: phase 2 study in ObesityNCT06143956
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 8 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07765511Obesity · Japan | 1 | Not yet recruiting | Jun 2027 | 60 |
| NCT07589608Overweight · United States | 2 | Recruiting | Sep 2027 | 400 |
| NCT07215559Obesity · United States, Argentina, Australia and more | 2 | Active, not recruiting | Mar 2027 | 200 |
| NCT06557356Obesity · United States, Singapore | 1 | Completed | Dec 12, 2025 | 132 |
| NCT06143956Obesity · United States, Argentina | 2 | Recruiting | Sep 2027 | 1,481 |
| NCT05887999Diabetes Mellitus, Type 1 · United States | 1 | Completed | Feb 21, 2024 | 30 |
| NCT05407961Diabetes Mellitus, Type 2 · Germany | 1 | Completed | Jan 12, 2024 | 90 |
| NCT04923269Healthy · Singapore | 1 | Completed | Oct 28, 2021 | 41 |
How it is read
Names in the registry
- “LY3532226”, 5 entries
- “Macupatide”, 3 entries
Conditions, from the studies’ own filings
- Obesity, 5 studies
- Diabetes Mellitus, Type 2, 1 study
- Diabetes Mellitus, Type 1, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.